104456-81-7

Basic information

• Product Name: methyl 5-fluoro-2-sulfanyl-benzoate
• Synonyms: methyl 5-fluoro-2-sulfanyl-benzoate
• CAS NO: 104456-81-7
• Molecular Weight: 186.207
• Mol File: 104456-81-7.mol

Chemical Properties

• CAS DataBase Reference: methyl 5-fluoro-2-sulfanyl-benzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 5-fluoro-2-sulfanyl-benzoate(104456-81-7)
• EPA Substance Registry System: methyl 5-fluoro-2-sulfanyl-benzoate(104456-81-7)

Safety Data

• Hazardous Substances Data: 104456-81-7(Hazardous Substances Data)

Upstream product

• 446-08-2 2-amino-5-fluorobenzoic acid 
• 67-56-1 methanol 
• 120121-07-5 5-fluoro-2-mercapto-benzoic acid 

Downstream Products

• 935433-73-1 2-((2-amino-4-carboxyphenyl) thio)-5-fluorobenzoic acid 
• 1186650-22-5 5-fluoro-2-(4-fluorophenyl)benzo[d]isothiazol-3(2H)-one 
• 18205-99-7 2-mercapto-N-phenylbenzamide 
• 2527-03-9 2-phenyl-1,2-benzisothiazolin-3-one 
• 1186650-26-9 5-fluoro-2-(4-methoxyphenyl)benzo[d]isothiazol-3(2H)-one 
• 1186646-43-4 2-(4-chlorophenyl)-5-fluorobenzo[d]isothiazol-3(2H)-one 
• 1186649-71-7 C₁₅H₁₂FNOS 
• 1186655-89-9 5-fluoro-2-(2-fluorophenyl)benzo[d]isothiazol-3(2H)-one 
• 1186646-30-9 5-fluoro-2-(3-fluorophenyl)benzo[d]isothiazol-3(2H)-one 

Relevant articles and documents

Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor

Ziresovir (RO-0529, AK0529) is reported here for the first time as a promising respiratory syncytial virus (RSV) fusion (F) protein inhibitor that currently is in phase 2 clinical trials. This article describes the process of RO-0529 as a potent, selective, and orally bioavailable RSV F protein inhibitor and highlights the in vitro and in vivo anti-RSV activities and pharmacokinetics in animal species. RO-0529 demonstrates single-digit nM EC50 potency against laboratory strains, as well as clinical isolates of RSV in cellular assays, and more than one log viral load reduction in BALB/c mouse model of RSV viral infection. RO-0529 was proven to be a specific RSV F protein inhibitor by identification of drug resistant mutations of D486N, D489V, and D489Y in RSV F protein and the inhibition of RSV F protein-induced cell-cell fusion in cellular assays.

HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS

ABSTRACT The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.